Trial intelligence / Profile preview

Donor-Derived CD19 CAR T Cells in Post-Transplant Relapsed CD19+ Acute Leukemia

2024-516091-15-00Phase 2Authorised

Sponsor: Aghia Sophia Children's Hospital of Athens
Start: Nov 2024
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Countries: 1

Overview

Phase 2, open-label, single-arm trial of DDCART-CD19 in acute lymphoblastic leukemia (ALL), sponsored by Aghia Sophia Children's Hospital of Athens. Primary endpoints: Complete remission rate at 30 days, DDCART-CD19 product purity and 2 more. Planned start Nov 2024; status: authorised.

Drugs

DDCART-CD19

Conditions

acute lymphoblastic leukemia (ALL)

Beyond the preview

Go deeper on 2024-516091-15-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-516091-15-00.